JPH05320056A - Tunica mucosa ventriculi-protecting agent containing chondroitin sulfuric acid - Google Patents

Abstract

PURPOSE:To provide the tunica mucosa ventriculi-protecting agent protecting gastric paries, improving the intake of nutrients and capable of being widely applied to usual physical fitness maintenance, fatigue recovery, dysphoria of gastric part.lower abdominal part, climacteric disturbance, drunken sickness, nutritive robustness, weak constitution, etc. CONSTITUTION:This tunica mucosa ventriculi-protecting agent having the above- mentioned effects contains (A) 1-40 pts.wt. of chondroitin sulfuric acid or its alkali metal or alkaline earth metal salt, (B) 0.5-20 pts.wt. of lecithin, and (C) 40-98.5 pts.wt. of a protein as essentral ingredients. The chondroitin sulfuric acid may be used in the form of its purified product or in the form of proteoglycan existing in the connective tissues, mainly cartilage, of an animal. In this case, the total amount of the protein in the proteoglycan and the newly added protein is controlled within the above-mentioned range. A protein originated from the proteoglycan, a protein originated from albumen, an animal protein such as all albumen, milk protein or gelatin, a vegetable protein such as soybean protein, etc., can be used as the protein.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a health promoting / maintaining agent, and more particularly to a chondroitin sulfate-containing gastric mucosa protective agent.

[0002]

BACKGROUND OF THE INVENTION Chondroitin sulfate is a kind of mucopolysaccharide generally distributed in connective tissues of animals mainly in cartilage. In the tissues, chondroitin sulfate binds to proteins and exists as proteoglycan.

[0003] Chondroitin sulfate is usually used as a sodium salt, and it is known pharmacologically that it has a fat serum clearing action, an anticoagulant action, a cell activating action, a detoxifying action, an analgesic action and the like. However, it has not yet been applied as a gastric mucosa protective agent.

[0004]

The inventors of the present invention have conducted extensive studies on the effective use of chondroitin sulfate as a health promoting / maintaining agent, and as a result, have found that chondroitin sulfate or its salt, lecithin and protein are contained in a certain proportion. The composition mixed in has a gastric mucosa protective action, protects the stomach wall, improves nutrition intake, and activates metabolism,
The inventors have found that they have excellent properties as a gastric mucosa protective agent that promote and maintain physical strength, and have completed the present invention.

[0005]

The gastric mucosa protective agent of the present invention comprises chondroitin sulfate or its alkali metal or alkaline earth metal salt 1-40 parts by weight, lecithin 0.5-20 parts by weight and protein 40-98. It is characterized by comprising 5 parts by weight.

In the present invention, chondroitin sulfate is
The purified product may be used, or the proteoglycan may be used. In this case, the equivalent amount of chondroitin sulfate in proteoglycan is within the above range, and the amount of protein in proteoglycan and the total amount of newly added protein may be within the above range.

[0007] To obtain chondroitin sulfate in the form of proteoglycan, for example, marine animals such as sharks and whales, mammals such as cows and pigs, or cartilage such as birds are used as raw materials.
It may be extracted by a known method such as a neutral salt method, an alkali method, an enzyme method, an autoclave method, etc. to remove fats and solids, and then dried. In addition, chondroitin sulfate or a salt thereof can be obtained in a purified state by removing fats and solids, followed by deproteinization with a proteolytic enzyme and purification according to a known method by alcohol precipitation.

The salt of chondroitin sulfate is usually
Although sodium salt is used, calcium salt, potassium salt and the like may be used.

In addition to proteoglycan-derived proteins, proteins derived from egg white or animal proteins such as whole egg white, milk protein, gelatin, etc., and vegetable proteins such as soybean protein, etc. can be used.

When the mixing ratio of chondroitin sulfate or its salt or lecithin is less than the above lower limit, the gastric mucosa protecting action becomes insufficient.

The gastric mucosa protective agent of the present invention contains vitamins A, B ₁ , B ₂ , B ₆ , B ₁₂ , C, D, in addition to chondroitin sulfate or its salt, lecithin and protein which are the main components.
E, pantothenic acid, nicotinic acid amide, biotin, folic acid, inositol, taurine, plant extracts such as ginseng extract, various amino acids, various minerals and the like can be appropriately mixed, but the total amount thereof is chondroitin sulfate or its It is preferably 10 parts by weight or less based on 100 parts by weight of the total amount of salt, lecithin and protein.

The gastric mucosa protective agent of the present invention is usually used as a liquid, granule, tablet, troche or capsule.

In use, the product of the present invention is usually taken in an amount of 1 to 2 g at a time, 1 to 3 times a day.

[0014]

The present invention will be described in more detail with reference to Examples and Formulations, but these do not limit the scope of the present invention.

Example (1) Preparation of Specimen The following liquid preparations (samples A and B) of the present invention and comparative liquid preparations (samples C and D) were prepared.

Specimen A: 10% aqueous solution of a composition containing 15% sodium chondroitin sulfate (molecular weight of about 10,000), 5% lecithin and 80% soybean protein Specimen B: 95% cartilage extract (13% sodium chondroitin sulfate, Equivalent to 82% of protein) and lecithin 5
A 10% aqueous solution of a composition containing 10% cartilage extract was obtained by spray-drying the extract obtained by keeping pig tracheal cartilage at 121 ° C. for 120 minutes, centrifuging it, and removing fat and solids. This product contained 13.7% sodium chondroitin sulfate and 86.3% protein. Specimen C: 1.5% sodium chondroitin sulfate aqueous solution Specimen D: 0.5% lecithin suspension

(2) Gastric mucosal protective action (a) Experimental method One male Wistar rat (body weight: 165 to 180 g)
A group of 5 animals was used. Rats that had been fasted at 10 o'clock the day before the experiment and further dehydrated at 15 o'clock were orally administered with 1 ml of a sample using a sonde, and 30 minutes later, similarly, 1 ml of absolute ethanol was orally administered, and 1 hour later, the stomach was removed and 1%. Number of lesions formed on gastric mucosa after soaking in formalin solution for 30 minutes and then performing a major curvature incision,
The sum of the areas obtained from the major axis x width of each damage was defined as the damaged area. Controls received saline.

(B) Result

[0019]

[Table 1]

As is clear from the above results, the product of the present invention,
That is, the group to which the sample A or the sample B was given had a smaller damaged area than the other groups, and showed strong resistance to gastric mucosal damage caused by alcohol.

(3) Acute toxicity The acute toxicity value by oral administration of the product of the present invention comprising 15% sodium chondroitin sulfate, 5% lecithin and 80% protein derived from cartilage was measured, and the following results were obtained.

[0022]

[Table 2]

As is clear from the above results, the product of the present invention has extremely low toxicity.

Formulation Example 1 Sodium chondroitin sulfate 20 g Lecithin 3 g Dry protein 77 g were mixed and granulated according to a conventional method.

Formulation Example 2 95 g of cartilage extract (corresponding to 13 g of sodium chondroitin sulfate and 82 g of protein) 5 g of lecithin were mixed and made into granules according to a conventional method and filled into capsules.

Formulation Example 3 Sodium chondroitin sulfate 30 g Lecithin 3 g Gelatin 67 g Retinol palmitate 9,000 Vitamin A unit Thiamine hydrochloride 100 mg Vitamin B ₂ 60 mg Vitamin B ₆ 60 mg Vitamin C 1,000 mg Calcium pantothenate 50 mg Nicotinic acid amide 200 mg Tocopherol acetate 50 mg Ergocalciferol 8,000 international units were mixed and granulated according to a conventional method.

Prescription Example 4 Thiamine hydrochloride 50 mg Vitamin B ₂ 25 mg Vitamin B ₆ 25 mg Calcium pantothenate 25 mg Nicotinic acid amide 100 mg Methionine 100 mg Sodium aspartate 300 mg Lysine hydrochloride 100 mg Carnitine 200 mg Carb glycerophosphate 300 mg in 100 g of the mixture of the formulation of Prescription Example 2 50 mg of the extract was added and mixed, and water was added to bring the total amount to 1,000 ml.

[0028]

The gastric mucosa protective agent of the present invention is widely applied to usual physical strength maintenance, fatigue recovery, stomach / lower abdominal discomfort, menopausal disorder, nausea, nutritional tonic, weak constitution and the like.

Claims (1)

[Claims] 1. A gastric mucosal protection comprising 1 to 40 parts by weight of chondroitin sulfate or its alkali metal or alkaline earth metal salt, 0.5 to 20 parts by weight of lecithin, and 40 to 98.5 parts by weight of protein. Agent.